Overview
The IgM B. miyamotoi test measures early antibodies against Borrelia miyamotoi, a spirochete related to the Borrelia burgdorferi sensu lato complex but classified within the relapsing fever group of Borrelia, rather than the classical Lyme-associated species. First identified in Japan in 1995, B. miyamotoi is now recognized in North America, Europe, and Asia as an emerging tick-borne pathogen transmitted by the same Ixodes ticks that spread Lyme disease.
The Role of IgM Antibodies
IgM antibodies are part of the immune system’s first response to infection. In B. miyamotoi disease (BMD), IgM typically becomes detectable within days to weeks of symptom onset. Since BMD often presents as an acute, flu-like illness with relapsing fever episodes, early IgM detection is an important indicator of recent or ongoing infection.
Clinical Significance of B. miyamotoi
Borrelia miyamotoi causes Borrelia miyamotoi disease (BMD), which shares clinical features with both Lyme disease and tick-borne relapsing fever. Characteristic findings include:
-
Flu-like symptoms: fever, chills, fatigue, muscle aches, headache
-
Relapsing fever: recurrent febrile episodes, typical of relapsing fever Borrelia
-
Neurological complications, such as meningoencephalitis, especially in immunocompromised patients
-
Absence of erythema migrans: unlike Lyme disease, BMD usually does not present with the bull’s-eye rash
Because BMD overlaps with other tick-borne illnesses but lacks hallmark Lyme signs, IgM testing helps clinicians suspect and identify this distinct infection.
Limitations and Considerations
-
Cross-reactivity: Antibodies may react with Lyme-related Borrelia antigens; specific testing helps distinguish BMD from Lyme disease.
-
Timing: IgM is most informative early; in longer illness courses, IgG testing may be more reliable.
-
Emerging recognition: As a relatively new pathogen, clinical experience and diagnostic access are more limited than for classical Lyme.
-
Geographic relevance: Positive results are most meaningful where Ixodes ticks are common (North America, Europe, Asia), and must be interpreted in light of exposure history.
Broader Context in Tick-Borne Illness
The discovery of B. miyamotoi underscores that tick-borne diseases extend beyond Lyme disease alone. Ixodes ticks can transmit Borrelia burgdorferi, Anaplasma, Babesia, and B. miyamotoi, making co-infections possible and often complicating clinical presentation. Including IgM B. miyamotoi testing alongside other tick-borne panels provides a more complete assessment when evaluating patients with fever, relapsing symptoms, or neurological issues after tick exposure.
Summary
The IgM B. miyamotoi test detects early antibody responses to a relapsing fever–type Borrelia increasingly recognized as an emerging human pathogen. A positive result suggests a recent or active infection, typically presenting as relapsing fever with flu-like illness, and in some cases, neurological involvement. Because B. miyamotoi disease differs clinically from classical Lyme borreliosis, results should always be interpreted in the context of symptoms, exposure history, and confirmatory testing for other tick-borne pathogens.
IgM B. miyamotoi
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.